DiaMedica Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
DiaMedica Therapeutics Inc. (DMAC) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 3.43 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-03-30
- DiaMedica Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-12-31 was 25.00K shares.
- DiaMedica Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-09-30 was 152.00K shares.
- DiaMedica Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 3.43M shares, a 84.12% increase from fiscal 2024.
- DiaMedica Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.86M shares, a 59.04% increase from fiscal 2023.
- DiaMedica Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.17M shares, a 15.59% increase from fiscal 2022.
- DiaMedica Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.01M shares, a 58.99% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2025-12-31 | 3.43M shares 10-K · filed 2026-03-30 | |||
| 2024-12-31 | 1.86M shares 10-K · filed 2025-03-17 | |||
| 2023-12-31 | 1.17M shares 10-K · filed 2024-03-19 | |||
| 2022-12-31 | 25.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | 177.00K shares derived: sum of 2 quarters · filed 2023-03-28 | 1.01M shares 10-K · filed 2023-03-28 | |
| 2022-09-30 | 152.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | 989.40K shares 10-Q · filed 2022-11-09 | ||
| 2022-06-30 | 837.40K shares 10-Q · filed 2022-08-11 | |||
| 2021-12-31 | 638.01K shares 10-K · filed 2022-03-14 | |||
| 2020-12-31 | 302.33K shares 10-K · filed 2021-03-10 | |||
| 2019-12-31 | 725.83K shares 10-K · filed 2020-03-23 | |||
| 2018-12-31 | 196.80K shares 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |